Mounjaro vs Trulicity in a clinical trial
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
The head to head trials keep stacking up in favor of Tirzepatide (Mounjaro, Zepbound).
In the past we’ve covered the head to head trial between the top 2 GLP1 Receptor Agonists — Tirzepatide and Semaglutide (Ozempic, Wegovy, Rybelsus):
GLP1.Guide Staff
Tirzpatide was the clear winner, creating more weight loss and positive health outcomes than Semaglutide did across the cohorts that were studied.
To be clear, both GLP1s are still a marvel of modern science and engineering, but it’s great to get data in a clinical setting that makes clear which is more effective.
This time, it’s Tirzepatide against Trulicity (Dulaglutide), a slightly older GLP1 that is also manufactured by Eli Lilly.
As you might imagine, Tirzepatide (Mounjaro in this case) was more effective than Trulicity. Tirzepatide achieved almost 3x more of weight loss in the study!
Read the press release for yourself here:
Check out the trial here:
Below, we’ll dive in to the study & results (there was one catch to using Mounjaro), pick out the key points and dive into what this could mean for Tirzepatide and GLP1s broadly:...
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
